BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kolberg HC, Akpolat-Basci L, Stephanou M, Aktas B, Hannig CV, Liedtke C. Neoadjuvant Chemotherapy with Docetaxel, Carboplatin and Weekly Trastuzumab Is Active in HER2-Positive Early Breast Cancer: Results after a Median Follow-Up of over 4 Years. Breast Care (Basel) 2016;11:323-7. [PMID: 27920624 DOI: 10.1159/000452079] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
Number Citing Articles
1 Fasching PA, Gaß P, Hein A. Neoadjuvant Treatment of Breast Cancer - Advances and Limitations. Breast Care (Basel) 2016;11:313-4. [PMID: 27920622 DOI: 10.1159/000452463] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
2 Jagosky M, Tan AR. Combination of Pertuzumab and Trastuzumab in the Treatment of HER2-Positive Early Breast Cancer: A Review of the Emerging Clinical Data. Breast Cancer (Dove Med Press) 2021;13:393-407. [PMID: 34163239 DOI: 10.2147/BCTT.S176514] [Reference Citation Analysis]
3 Xie Y, Wu S, Zhang Y, Li J, Mo M, Shao Z, Liu G. Optimal Duration of Neoadjuvant Taxane and Carboplatin Combined With Anti-HER2 Targeted Therapy for HER2-Positive Breast Cancer. Front Oncol 2021;11:686591. [PMID: 34168999 DOI: 10.3389/fonc.2021.686591] [Reference Citation Analysis]
4 He X, Dai X, Ji J, Liu H, Shi G, Yeung SJ. Nine-Year Median Follow-up of Ccardiotoxicity and Efficacy of Trastuzumab Concurrently With Anthracycline-Based and Anthracycline-Free Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer Patients. Clin Breast Cancer 2021:S1526-8209(21)00136-1. [PMID: 34312098 DOI: 10.1016/j.clbc.2021.05.008] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Xu Q, Yuanyuan L, Jiejing Z, Jian L, Qingyu L, Lingya C, Ying L, Changchen S, Yangling L, Wei Y. Cost-effectiveness of paclitaxel, doxorubicin, cyclophosphamide and trastuzumab versus docetaxel, cisplatin and trastuzumab in new adjuvant therapy of breast cancer in china. Cost Eff Resour Alloc 2021;19:11. [PMID: 33622356 DOI: 10.1186/s12962-021-00264-w] [Reference Citation Analysis]